Analyst Tazeen Ahmad from Bank of America Securities maintained a Buy rating on BioNTech SE and keeping the price target at $134.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tazeen Ahmad’s rating is based on BioNTech SE’s strategic focus on developing combination therapies within its oncology pipeline. The company is actively pursuing innovative approaches by integrating immunomodulators, targeted therapies, and its mRNA platform to address high unmet needs in oncology. This strategy is expected to yield significant differentiation and value, as evidenced by several promising data points and upcoming catalysts.
Furthermore, BioNTech’s management has demonstrated a diligent approach to capital allocation, emphasizing the advancement of high-value programs while maintaining a strong balance sheet. The anticipated data releases and potential commercial launches in the coming years, particularly in 2026, are seen as pivotal for the company’s long-term growth and success. These factors collectively underpin the Buy rating with a price objective of $134.
In another report released today, Wells Fargo also maintained a Buy rating on the stock with a $150.00 price target.